Daily Roundup

LIN.ASX NHC.ASX 360.ASX FBR.ASX NEU.ASX

Lindian-RA Acquires Operating MREC Facility

Lindian Resources Ltd has executed a binding term sheet to acquire 100% of an existing Mixed Rare Earths Carbonate (MREC) Processing Facility in Kazakhstan, transforming its business from concentrate-only production to high-value MREC production. The acquisition, structured through an Incorporated Joint Venture with local partner RA-Group LLP, will provide Lindian access to the Summit Atom Rare Earth Company Arctic LLP (SARECO) MREC Facility and associated infrastructure.

This strategic move is expected to significantly enhance Lindian's economics, as MREC production attracts premium payabilities compared to concentrate-only sales. The Kangankunde Rare Earths Project and SARECO MREC Facility are slated to be fully operational within ~9 months, with Lindian supplying around 12,500 tonnes per annum of high-quality Monazite Concentrate from Stage 1 of Kangankunde to the downstream Lindian-RA JV.

The $15 million purchase price represents a fraction of the estimated $500 million capital cost to build a new MREC Facility. Strategically located in Stepnogorsk, Kazakhstan, the SARECO Facility benefits from access to low-cost power, water, sulphuric acid, reagents, and skilled labour. Lindian will retain operational oversight and exclusive marketing rights for all MREC product produced.

New Hope Corporation Extends On-Market Share Buy-Back

New Hope Corporation Ltd has announced an extension of its existing on-market share buy-back program to March 2027, as part of its ongoing capital management strategy to enhance shareholder value. The buy-back, initially announced in March 2025, will continue to be executed at the company's discretion, considering factors such as market conditions, the prevailing share price, future capital requirements, and any unforeseen developments.

Consistent with the requirements of the Corporations Act, New Hope will immediately cancel any shares acquired under the buy-back. The extension does not require shareholder approval and falls within the '10/12' limit permitted under the Act.

Life360 Investor Presentation Highlights Growth

Life360's investor presentation showcases the company's impressive global scale, with 95.8 million monthly active users across 180+ countries and 16% U.S. smartphone penetration. The company reported robust financial performance in FY'25, with revenue of $489.5 million and an Adjusted EBITDA margin of 19%.

Beyond its core location sharing, family messaging, and driving safety features, Life360 is expanding into the pet space with the launch of a Pet GPS device and a Pet Finder Network. The company's strong user engagement, with a 60 Net Promoter Score, underpins its large addressable market opportunities in subscription services, advertising, item tracking, and pet tracking, as well as potential future expansion into adjacent markets.

Life360 Reports Record Q4 2025 Results

Life360 capped off a banner year in 2025, reporting record-breaking results across key metrics. The company's monthly active users reached approximately 95.8 million, up 20% year-over-year, while annual global net additions of paying circles hit a record 576,000, bringing the total to 2.8 million.

Total annual revenue grew 32% year-over-year to $489.5 million, and Adjusted EBITDA surged 105%. Life360 made significant progress in 2025, including the introduction of Pet GPS, the acquisition of Fantix, and the completion of the Nativo acquisition, solidifying its position as a multi-engine platform.

Looking ahead to 2026, Life360 expects revenue growth acceleration driven by both its core subscription business and the scaling of its advertising platform, while remaining committed to balancing growth investment with margin expansion.

FBR secures binding WaaS Offtake Agreement

FBR Ltd has secured a binding Wall as a Service® (WaaS®) Offtake Agreement with Victorian-based modular building company AMOVEO. Under the agreement, AMOVEO is committed to purchasing a minimum of 5,400 vertical square metres of wall construction from FBR over a 24-month term, with a contract value of $400,000 to $450,000.

In addition, FBR has signed a strategic Memorandum of Understanding with AMOVEO and registered national builder ASD Corporation Australia to jointly develop and deliver a hybrid robotic-modular construction solution across Australia. The partnership will integrate FBR's Hadrian robotic blocklaying technology with AMOVEO's factory-built modular prefabricated service cores, aiming to drastically reduce build times and address housing supply constraints.

Following the successful construction of an initial batch of demonstration homes, the companies intend to enter into a 5-year Commercialisation Agreement to roll out the combined robotic and modular construction system nationally.

Acadia to request CHMP re-examination for trofinetide

Neuren Pharmaceuticals' partner, Acadia Pharmaceuticals, plans to request re-examination of the European Medicines Agency's CHMP opinion that recommended refusal of marketing authorization for trofinetide to treat Rett syndrome. Trofinetide is already approved in the United States, Canada, and Israel, representing the first and only treatment approved for Rett syndrome.

Neuren's CEO expressed full support for Acadia's plan to re-examine the CHMP opinion, noting the unmet medical need in Europe remains substantial and urgent. While the pivotal LAVENDER clinical trial successfully met its co-primary and key secondary endpoints, the CHMP cited perceived deficits, including the limited magnitude of the treatment effect and the influence of patient discontinuations on the assessment of longer-term outcomes.